JAC Advance Access originally published online on April 22, 2008
Journal of Antimicrobial Chemotherapy 2008 62(2):426-428; doi:10.1093/jac/dkn167
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters to the Editor |
Comment on: Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
1 Pathology Department, The University of Hong Kong, Pok Fu Lam, Hong Kong, Hong Kong SAR 2 NexBio Inc., 10665 Sorrento Valley Road, San Diego, CA 92121, USA 3 Departments of Chemical Physiology and Molecular Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
* Corresponding author. Tel: +1-858-452-2631; Fax: +1-858-452-0133; E-mail: ffang{at}nexbio.com
Zhang1 questioned the validity of developing a sialidase fusion protein (DAS181) as an experimental drug against influenza. He raised two main concerns—first, that sialidase treatment would result in a greater chance of bacterial infection by exposing novel cryptic binding sites to bacterial pathogens and second, that influenza virus (IFV) receptors may be different from sialic acids (SA); thus, sialidase treatment may be ineffective. Although we agree with Zhang that the safety and efficacy of any novel therapeutic candidate, including DAS181, needs to be evaluated cautiously, statements made by him on sialidase treatment and the general view presented on the role of SA in IFV infection are either incomplete or incorrect. We thus offer the following corrections.
It is known that IFV infection is associated with an increased risk of secondary infection by Streptococcus pneumoniae.2 A clear distinction that needs to be made, however, is whether the secondary S. pneumoniae infection arises from viral neuraminidase (a sialidase) by itself or from the secondary effects of IFV infection. Scientific evidence clearly supports the latter, as influenza infection in the trachea and bronchus causes much deeper changes to the airway epithelium than could be caused by treatment of the epithelial cell surface with a sialidase. Influenza infection in humans results in extensive denudation of the ciliated epithelial cells down to the basal cells, or even to the basement membrane.3 Similar changes are also present in mice infected with IFV.4 When S. pneumoniae infection does occur, it is seen at the exposed layers of basal cells or basement membrane, but not on the intact epithelial surface.4 Thus, contrary to Zhang's concern, the data from Plotkowski et al.4 provide direct evidence that increased S. pneumoniae infection is the result of airway epithelial damage caused by IFV infection. By inhibiting IFV infection as the primary cause of the epithelial damage, sialidase treatment can protect the airway epithelium from inflammation and denudation and thus can potentially prevent secondary bacterial infection.
Zhang suggested that sialidase increases S. pneumoniae adherence by exposing cryptic receptors. SA is usually connected via 
2-6 or 2-3 linkage to either Galβ1-4GlcNAc or Galβ1-3GalNAc. Thus, the inner polysaccharide or ‘cryptic’ fragments exposed after sialidase treatment would be predominantly Galβ1-4GlcNAc and Galβ1-3GalNAc. Using an established methodology, we stained normal and DAS181-treated human tracheal tissue sections with lectins. We observed that DAS181 treatment abolished SA binding by Sambucus nigra agglutinin (SNA) (which binds SA2-6). Importantly, Galβ1-4GlcNAc [bound by Datura stramonium agglutinin (DSA)] was abundantly present on the ciliated surface of tracheal epithelium in the native state as well as following DAS181 treatment (Figure 1). Consistent with our observation, the matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) glycan profile analysis of the human bronchial epithelium also revealed abundant Galβ1-4GlcNAc structures in the absence of sialidase.5 Galβ1-3GalNAc expression was low and restricted to goblet cells and basal cells in the control tissue; it was modestly increased only in the goblet cells after DAS181 treatment (Figure 1). Noticeably, mass spectrometric analysis has also revealed numerous Galβ1-4GlcNAc structures in the normal lung tissue (http://www.functionalglycomics.org/glycomics/publicdata/glycoprofiling.jsp?species=Human). Together, these studies demonstrate that the inner polysaccharide structures exposed by desialylation already exist on the normal respiratory surface. As a result, sialidase treatment is unlikely to introduce de novo bacterial adhesion sites.
|
We conducted further studies to evaluate whether sialidase treatment would increase colonization of respiratory epithelial cells by S. pneumoniae, Haemophilus influenzae or Pseudomonas aeruginosa. DAS181 treatment of A549 cells did not increase cell adhesion by these bacteria over a broad range of bacterial inputs (L. M. Aschenbrenner and F. Fang, unpublished results). In the well-differentiated human airway epithelium (HAE) cultures, DAS181 treatment did not increase adhesion of S. pneumoniae (Figure 2) and did not result in any cytopathic effect. Together, our findings support previous observations, indicating that removing SA alone does not have a significant impact on bacterial cell adhesion.
|
Zhang also raised concerns over the entry of IFV into desialylated cells by citing isolated reports that investigate aspects of IFV entry in cell culture models. Evidence accumulated over the past six decades has indisputably demonstrated the key role of SA as the IFV receptor.6,7 The purpose of these cited reports was to investigate other aspects of IFV entry. None of them disputed the role of SA in promoting IFV infection. For example, although Stray et al.8 demonstrated non-SA-dependent entry of IFV into cells at high doses, they also demonstrated 90% to 99.999% reduction of IFV multicycle infectivity in desialylated Madin-Darby canine kidney (MDCK) cells. Chu and Whittaker9 showed that glycoproteins which contain sialylated N-linked glycans were critical for productive entry of IFV into cells. These results in fact support the role of sialylated glycans as the receptors of IFV.
DAS181 (FludaseTM) is being developed as a potential broad-spectrum prophylactic and therapeutic agent for seasonal influenza-like illness and for pandemic influenza. We have reported results that demonstrate potent in vitro and in vivo activities of DAS181 against a broad panel of IFV strains, including the highly pathogenic H5N1 strain.10,11 In order to fully address the legitimate questions on drug safety, in the ongoing Phase 1 clinical trial, we are closely monitoring the status of bacterial colonization among an extensive panel of safety parameters.
Preparing the world to safeguard itself against an influenza pandemic poses daunting challenges to the scientific community and industry alike. We genuinely welcome constructive scientific input from our colleagues and focus our effort on the important task in front of us.
 |
Transparency declarations |
|---|
 Top Transparency declarations References |
|---|
L. M. A., J. C. P., E. R. C., M. P. M, D. F. W., M. Y. and F. F. have shares in NexBio Inc., which is the sponsor of DAS181 development. J. M. N.: none to declare.
|
Footnotes |
|---|
These authors contributed equally to this correspondence. 
|
Acknowledgements |
|---|
This study was supported by funding from the Research Grants Council, Hong Kong SAR, and NIH grants 2R44AI056786 and 1U01AI070281.
|
References |
|---|
|
TopTransparency declarationsReferences |
|---|
1 Zhang H. Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother (2008) 62:219–23.
2
van der Sluijs KF, van Elden LJ, Nijhuis M, et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol (2006) 290:L194–9.
3
Walsh JJ, Dietlein LF, Low FN, et al. Bronchotracheal response in human influenza. Type A, Asian strain, as studied by light and electron microscopic examination of bronchoscopic biopsies. Arch Intern Med (1961) 108:376–88.
4 Plotkowski MC, Puchelle E, Beck G, et al. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis (1986) 134:1040–4.[Web of Science][Medline]
5 Chandrasekaran A, Srinivasan A, Raman R, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol (2008) 26:107–13.[CrossRef][Web of Science][Medline]
6 Paulson JC. Interactions of Animal Viruses with Cell Surface Receptors—Conn M, ed. (1985) New York, NY: Academic Press. 131–219.
7 Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 69:531–69.[CrossRef][Web of Science][Medline]
8
Stray SJ, Cummings RD, Air GM. Influenza virus infection of desialylated cells. Glycobiology (2000) 10:649–58.
9
Chu VC, Whittaker GR. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci USA (2004) 101:18153–8.
10
Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 50:1470–9.
11 Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis (2007) 196:1493–9.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. W. Y. Chan, M. C. W. Chan, A. C. N. Wong, R. Karamanska, A. Dell, S. M. Haslam, A. D. L. Sihoe, W. H. Chui, G. Triana-Baltzer, Q. Li, et al. DAS181 Inhibits H5N1 Influenza Virus Infection of Human Lung Tissues Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3935 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Duez, N. Sixt, and A. Pechinot Influenza virus infection: don't forget the role of the mucociliary system! J. Antimicrob. Chemother., February 1, 2009; 63(2): 421 - 422. [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza--author's response J. Antimicrob. Chemother., August 1, 2008; 62(2): 428 - 429. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||